Inhibitors of programmed death 1 (PD-1) protein or its ligand (PD-L1) have shown remarkable clinical benefit in many cancers. 1 One emerging biomarker of response to anti–PD-1 therapy is the tumor ...
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback